« Back
Home /
Pipobroman

Pipobroman

€100.00

Excl. VAT

Item no.	HY-16398-100mg
Manufacturer	MedChem Express
CASRN	54-91-1
Amount	100 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer Bone Cancer
Type	Inhibitors
Specific against	other
Purity	99.81
Formula	C10H16Br2N2O2
Citations	[1]Jean-Jacques Kiladjian, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011 Oct 10;29(29):3907-13. [2]Charles Cassius, et al. Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma. J Invest Dermatol. 2016 Jun;136(6):1302-1305.
Smiles	O=C(N1CCN(C(CCBr)=O)CC1)CCBr
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	54-91-1
Available
Product Description	Pipobroman is a bromide derivative of piperazine and acts as an alkylating agent. Pipobroman plays its role by inhibiting DNA and RNA polymerase or by reducing pyrimidine nucleotide incorporation into DNA. Pipobroman can be used for the cancer research, including polycythemia vera, myeloproliferative neoplasm, and AML et.al[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-programmed cell death
Molecular Weight	356.05
Clinical Information	Launched
Solubility	DMSO : ≥ 36 mg/mL
Pathway	Cell Cycle/DNA Damage
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-16398-100mg-safety-datasheet.pdf